NanoSmart Pharmaceuticals has entered into a research collaboration with the University of California Los Angeles (UCLA) to continue development of NanoSmart’s drug delivery platform for the treatment of cancer and other diseases.   NanoSmart’s drug delivery system uses human autoimmune antibodies that target many different types of tumors and combined with approved cancer drugs, offers the potential to create a broad range of next-generation, safer, and more effective cancer drug pr...